Above €217.20: Sartorius Stedim Biotech stock breaks through its resistance
Sartorius Stedim Biotech is accelerating mid-morning, in an SBF 120 oriented upwards. The stock extends a recovery that began several weeks ago and is approaching levels not seen in recent months. Bioprocess stocks are benefiting from a renewed appetite in a Paris market that is advancing.
A resistance breakthrough that extends a 15% gain over one month
The Sartorius Stedim Biotech stock is gaining 4.57% to €219.60, compared to €210 at yesterday's close. It ranks among the strongest gainers in the SBF 120, which is up 0.66%. During the session, the stock broke through its €217.20 resistance and is maintaining above it, which fuels an already solid momentum: +15.4% over one month.
The price is 8.95% above its 20-day moving average and 20.53% above its 200-day moving average. The RSI at 61 remains far from extreme zones, so the movement is nothing like an isolated surge. The next technical level is the €223 resistance, at approximately 1.6% of the current price.
A consensus valuing the stock at 44 times expected earnings
Analyst opinions have already accompanied the progress of recent days, two of them having been published last Thursday and Friday, as detailed by the analyst upgrade of October 2. According to the consensus of surveyed analysts, the stock is trading at approximately 44 times the earnings of the current fiscal year and 36.7 times those of the following fiscal year. When the group published its first-half 2026 results on July 22, it confirmed its annual targets following a half-year driven by recurring activities. Over three months, the stock is up 21.86%, and the gain reaches 10.57% over one year.
